Vairo F, Haider N, Kock R, Ntoumi F, Ippolito G, Zumla A, 2019. Chikungunya: epidemiology, pathogenesis, clinical features, management, and prevention. Infect Dis Clin North Am 33: 1003–1025.
Hennessey MJ et al., 2018. Seroprevalence and symptomatic attack rate of chikungunya virus infection, United States Virgin Islands, 2014–2015. Am J Trop Med Hyg 99: 1321–1326.
Petersen LR, Powers AM, 2016. Chikungunya: epidemiology. F1000Res 5: F1000 Faculty Rev-82.
Gonzalez-Sanchez JA, Ramirez-Arroyo GF, 2018. Chikungunya virus: history, geographic distribution, clinical picture, and treatment. P R Health Sci J 37: 187–194.
Economopoulou A, Dominguez M, Helynck B, Sissoko D, Wichmann O, Quenel P, Germonneau P, Quatresous I, 2009. Atypical Chikungunya virus infections: clinical manifestations, mortality and risk factors for severe disease during the 2005–2006 outbreak on Reunion. Epidemiol Infect 137: 534–541.
Pan American Health Organization , 2011. Guidelines for Preparedness and Response for Chikungunya Virus Introduction in the Americas. Washington, DC: Pan American Health Organization.
Powers AM, 2018. Vaccine and therapeutic options to control chikungunya virus. Clin Microbiol Rev 31: e00104-16.
DeFilippis VR, 2022. Chikungunya virus vaccines: platforms, progress, and challenges. Curr Top Microbiol Immunol 435: 81–106.
Valneva , 2022. Valneva Successfully Completes Pivotal Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate. Available at: https://valneva.com/press-release/valneva-successfully-completes-pivotal-phase-3-trial-of-single-shot-chikungunya-vaccine-candidate/. Accessed April 30, 2022.
U.S. National Library of Medicine , 2022. ClinicalTrial: Chikungunya Vaccine. Available at: https://clinicaltrials.gov/ct2/results?cond=chikungunya+vaccine&term=&cntry=&state=&city=&dist=. Accessed April 30, 2022.
Pan American Health Organization , 2022. Chikungunya. Available at: https://www.paho.org/en/topics/chikungunya. Accessed April 30, 2022.
Feldstein LR, Ellis EM, Rowhani-Rahbar A, Halloran ME, Ellis BR, 2016. The first reported outbreak of chikungunya in the U.S. Virgin Islands, 2014–2015. Am J Trop Med Hyg 95: 885–889.
R Core Team , 2022. R: A Language and Environment for Statistical Computing. Available at: https://www.R-project.org/. Accessed April 30, 2022.
US Census Bureau , 2010. 2010 Census Island Areas: United States Virgin Islands. Available at: https://www.census.gov/newsroom/releases/archives/2010_census/press-kits/island-areas.html. Accessed February 4, 2019.
Olson D, Rick AM, Krager S, Lamb M, Asturias EJ, 2018. Vaccine demand and willingness-to-pay for arbovirus vaccines: a cross-sectional survey in rural Guatemala. Pediatr Infect Dis J 37: 1184–1189.
Harapan H, Anwar S, Setiawan AM, Sasmono RT, Aceh Dengue S, 2016. Dengue vaccine acceptance and associated factors in Indonesia: a community-based cross-sectional survey in Aceh. Vaccine 34: 3670–3675.
Yeo HY, Shafie AA, 2018. The acceptance and willingness to pay (WTP) for hypothetical dengue vaccine in Penang, Malaysia: a contingent valuation study. Cost Eff Resour Alloc 16: 60.
Hadisoemarto PF, Castro MC, 2013. Public acceptance and willingness-to-pay for a future dengue vaccine: a community-based survey in Bandung, Indonesia. PLoS Negl Trop Dis 7: e2427.
Wong LP, Alias H, Hassan J, AbuBakar S, 2017. Attitudes towards Zika screening and vaccination acceptability among pregnant women in Malaysia. Vaccine 35: 5912–5917.
Marban-Castro E, Villen-Gonzalvo A, Enguita-Fernandez C, Romero-Acosta KC, Marin-Cos A, Arrieta GJ, Mattar S, Menendez C, Maixenchs M, Bardaji A, 2020. Acceptability of a hypothetical Zika vaccine among women from Colombia and Spain exposed to ZIKV: a qualitative study. Vaccines (Basel) 8: 580.
Larson HJ, Gakidou E, Murray CJL, 2022. The vaccine-hesitant moment. N Engl J Med 387: 58–65.
|Past two years||Past Year||Past 30 Days|
|Full Text Views||35||35||5|
Chikungunya virus, a mosquito-borne alphavirus, causes acute febrile illness with polyarthralgia. Groups at risk for severe disease include neonates, people with underlying medical conditions, and those aged ≥ 65 years. Several chikungunya vaccines are in late clinical development with licensure expected in the United States during 2023. We administered a questionnaire to randomly selected households in the U.S. Virgin Islands (USVI) to assess interest in a hypothetical chikungunya vaccine. Estimates were calibrated to age and sex of USVI population, and univariate and multivariable analyses were performed. Of 966 participants, 520 (adjusted 56%, 95% CI = 51–60%) were interested in receiving the vaccine. Of 446 participants not interested in vaccination, 203 (adjusted 47%, 95% CI = 41–52%) cited safety concerns as the reason. Educational efforts addressing vaccine safety concerns and risk factors for severe disease would likely improve vaccine acceptability and uptake among those most at risk.
Disclosures: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC.
Authors’ addresses: Emily J. Curren and Morgan J. Hennessey, Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, CO, and Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, E-mails: firstname.lastname@example.org and email@example.com. Esther M. Ellis, United States Virgin Islands Department of Health, Christiansted, U.S. Virgin Islands, E-mail: firstname.lastname@example.org. Mark J. Delorey, Marc Fischer, and J. Erin Staples, Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, CO, E-mails: email@example.com, firstname.lastname@example.org, and email@example.com.